TCM
APLS

Teza Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Teza Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,855
Closed -$259K – 318
2025
Q1 		$259K Buy
+11,855
New +$327K 0.12% 301

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Teza Capital Management's APLS Position: Q2 2025 in Review

Teza Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2025, closing a stake of 11,855 shares — an estimated $259K sold.

Teza Capital Management first reported a position in APLS in Q1 2025 and held it in 1 quarter. The position peaked at $259K in Q1 2025. 247 funds tracked by Wall St. Rank hold APLS as of Q2 2025.

  • Teza Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Teza Capital Management sold 11,855 Apellis Pharmaceuticals shares in Q2 2025, an estimated $259K.
  • Teza Capital Management first reported a position in Apellis Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Teza Capital Management's Apellis Pharmaceuticals position peaked at $259K in Q1 2025.
  • 247 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2025.

Based on Teza Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.